Get started
Author

Alison H. M. Reid

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
2008 · Gerhardt Attard, Alison H.M. Reid, et al. · Journal of Clinical Oncology · 900
PDF
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
2009 · Gerhardt Attard, Alison H.M. Reid, et al. · Journal of Clinical Oncology · 606
Characterization of ERG , AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
2009 · Gerhardt Attard, Joost F. Swennenhuis, et al. · Cancer Research · 533
PDF
Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
2010 · Alison H.M. Reid, Gerhardt Attard, et al. · Journal of Clinical Oncology · 395
PDF
Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer
2011 · Gerhardt Attard, Alison H. M. Reid, et al. · The Journal of Clinical Endocrinology & Metabolism · 282
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
2009 · L.R. Molife, G. Attard, et al. · Annals of Oncology · 184
Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven
2009 · Gerhardt Attard, Alison H.M. Reid, et al. · Cancer Research · 168
PDF
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
2007 · Alison Reid, Laura Vidal, et al. · European Journal of Cancer · 155
Complex patterns of ETS gene alteration arise during cancer development in the human prostate
2007 · J Clark, G Attard, et al. · Oncogene · 149
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study
2012 · David Olmos, Daniel Brewer, et al. · The Lancet Oncology · 112
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer
2008 · on behalf of the Transatlantic Prostate Group, G Attard, et al. · British Journal of Cancer · 109
PDF
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
2010 · L R Molife, P C Fong, et al. · British Journal of Cancer · 84
PDF
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
2008 · S P Blagden, L R Molife, et al. · British Journal of Cancer · 81
PDF
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
2006 · G Attard, D Sarker, et al. · British Journal of Cancer · 74
PDF
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors
2009 · Richard D. Baird, Jos Kitzen, et al. · Molecular Cancer Therapeutics · 47
PDF
Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study
2018 · Antoine Thiery-Vuillemin, Mads Hvid Poulsen, et al. · ESMO Open · 44
PDF
The contemporary management of prostate cancer
2025 · Deep Chakrabarti, Peter Albertsen, et al. · CA A Cancer Journal for Clinicians · 40
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin
2009 · M. Ranson, H. Shaw, et al. · Cancer Chemotherapy and Pharmacology · 36
A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors
2009 · Alison H.M. Reid, Andrew Protheroe, et al. · Clinical Cancer Research · 35
Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first‐line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)
2019 · Ben Tran, Jose M. Ruiz‐Morales, et al. · Cancer Medicine · 28
PDF
PEARLS – A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA‐avid pelvic and/or para-aortic lymph nodes at presentation
2022 · Julia Murray, Clare Cruickshank, et al. · Clinical and Translational Radiation Oncology · 16
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
2021 · Rebeca Lozano, David Lorente, et al. · Cancers · 16
Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer
2017 · Chey Loveday, Kevin Litchfield, et al. · Oncotarget · 12
PDF
Stereotactic Body Radiation Therapy for Oligoprogressive Disease in Androgen-Suppressed Prostate Cancer: Primary Endpoint Analysis of the TRAP Trial
2025 · Priyanka Patel, Sabine Dreibe, et al. · International Journal of Radiation Oncology*Biology*Physics · 10
Management of Testicular Cancer
2025 · Daniele Raggi, Deep Chakrabarti, et al. · JCO Oncology Practice · 8
Works count: 50
Citation count: 4,162
H-index: 20
I10-index: 23
Year
Topic
Type